Health
Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease | Antibodies | News Channels – PipelineReview.com
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling.
Details
Category: Antibodies
Published on Tuesday, 01 September 2020 11:52
Hits: 106
Potential to be the first approved therapeutic for the treatment of Non-responsive Celiac Disease
PRV-015 (anti-interleukin-15) is the first investigational product to show both a reduction in gluten-induced symptoms and in markers of intestinal inflammation in a placebo-controlled trial in celiac subjects
OLDWICK, NJ, USA I August 31, 2020 I Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company…
-
General21 hours agoDonald Trump and the ghost of Al Capone • Inside Story
-
General13 hours agoFrench far-right supporters rally against Le Pen conviction in Paris
-
Business5 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Business9 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?